Paid Clinical Trials Nashua

Discover 217 paid clinical trials in Nashua, New Hampshire. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 217

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Manchester NH, Burlington MA, Winchester MA, Newburyport MAshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Boston MA, Providence RI, Lebanon NH, Scarborough MEshow 104 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting

PHASE3

Sponsor:

AstraZeneca

Location:

Manchester NH, Hooksett NH, Boston MA, Worcester MAshow 143 more

Code:

NCT05952557

Conditions

Breast Cancer, Early Breast Cancer

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Camizestrant

Tamoxifen

Anastrozole

Letrozole

Exemestane

Odronextamab & CemiplimabA Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

Recruiting

PHASE1

Sponsor:

Regeneron Pharmaceuticals

Location:

Boston MA, Lebanon NH, New York NY, Philadelphia PAshow 5 more

Code:

NCT02651662

Conditions

Relapsed/Refractory Aggressive B-Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemiplimab

odronextamab

EtrasimodA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Recruiting

PHASE2

Sponsor:

Pfizer

Location:

Boston MA, Lebanon NH, Rochester NY, Cleveland OHshow 14 more

Code:

NCT05287126

Conditions

Ulcerative Colitis

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Etrasimod

Observational StudyInternational Registry for Men With Advanced Prostate Cancer (IRONMAN)

Recruiting

Sponsor:

Prostate Cancer Clinical Trials Consortium

Location:

Boston MA, Worcester MA, New Haven CT, New York NYshow 41 more

Code:

NCT03151629

Conditions

Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Standard of Care

Observational StudyA Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting

Sponsor:

Target PharmaSolutions, Inc.

Location:

Worcester MA, Quincy MA, Lebanon NH, Bronx NYshow 51 more

Code:

NCT03661866

Conditions

Atopic Dermatitis

Alopecia Areata

Hidradenitis Suppurativa

Vitiligo

Psoriasis

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Burlington MA, Boston MA, Foxboro MA, Lake Success NYshow 62 more

Code:

NCT05147220

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

TAK-279A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting

PHASE3

Sponsor:

Takeda

Location:

Portsmouth NH, Lebanon NH, Bronx NY, New York NYshow 85 more

Code:

NCT06550076

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAK-279

HZN-1116A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Recruiting

PHASE2

Sponsor:

Amgen

Location:

Boston MA, New York NY, Columbia MD, Duncansville PAshow 14 more

Code:

NCT06312020

Conditions

Sjogren's Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

HZN-1116

Placebo